Physician profile
Peter Guhl
NPI 1538109392
$4,678.22
in general payments reported to CMS, 2019-2025
14 companies · $735 in 2025
The $735 reported for 2025 was more than what 91% of Vision Therapy providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,123 · 2020: $41.97 · 2021: $293 · 2022: $537 · 2023: $417 · 2024: $531 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,138.22 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $889.28 | 2022-2025 | Infuse, Xiidra, Miebo |
| Alcon Vision LLC | $522.79 | 2019-2024 | Total30, Dailies Total1, Precision 1 |
| Lkc Technologies, INC. | $258.07 | 2024-2025 | |
| Abbvie INC. | $123.33 | 2022 | |
| Topcon Healthcare, INC. | $115.13 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $108.92 | 2025 | |
| Dompe US, INC. | $106.09 | 2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $101.04 | 2019 | |
| Horizon Therapeutics Plc | $93.06 | 2022 | |
| Abb Con-Cise Optical Group LLC | $85.56 | 2022 | |
| Sun Pharmaceutical Industries INC. | $72.93 | 2019-2022 | |
| Allergan, INC. | $48.49 | 2021 | |
| Mallinckrodt Hospital Products INC. | $15.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Guhl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.